{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014334","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.896088+00:00","generated_at":"2026-05-30T05:21:02.897886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"uniQure Q3 net loss $44.4M; cash runway through 2027; FDA meeting for Huntington gene therapy","bullets":["Net loss $44.4M ($0.91/share) vs $89.6M ($1.88) in Q3 2023; revenue $2.3M (up from $1.4M).","Cash $435.2M as of Sep 30; retired $50M debt; expects cash runway through end of 2027.","Sold Lexington facility and restructured, cutting ~65% of roles (300) and reducing cash burn by $70M/year.","Type B FDA meeting scheduled late Nov 2024 to discuss accelerated pathway for AMT-130 in Huntington's disease.","Positive interim data at 24 months: AMT-130 high dose showed significant slowing of disease progression (p=0.007) and NfL reduction (p=0.02)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014334","json":"https://secwatch.observer/filing/0001558370-24-014334.json","markdown":"https://secwatch.observer/filing/0001558370-24-014334.md","text":"https://secwatch.observer/filing/0001558370-24-014334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/0001558370-24-014334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/qure-20241105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:21:02.897886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}